Four-weekly Low-dose Gemcitabine and Paclitaxel in Patients With Platinum-resistant Urothelial Cancer and Performance Status 2/3.
BACKGROUND/AIM
Immune check-point inhibitors are often unsuitable for patients with urothelial cancer with a poor performance status (PS 2 or 3). The aim of this study was to assess the safety and usefulness of combined therapy with low-dose gemcitabine and paclitaxel every 4 weeks.


PATIENTS AND METHODS
Thirty patients were treated with gemcitabine (700 mg/m2 on day 1) and paclitaxel (70 mg/m2 on day 1) every 4 weeks. The predictive value of human antigen-R (HuR) and class III β-tubulin (TUBB3) were also analyzed.


RESULTS
There was no severe adverse event nor significant decrease in quality of life. The survival period of patients treated with this regimen was significantly longer than that of those treated with best supportive care. The expression pattern of HuR negativity and TUBB3 positivity predicted significantly worse overall survival.


CONCLUSION
Our regimen was suitable as second-line therapy for patients with advanced platinum-resistant UC with a poor PS. However, a HuR-negative and TUBB3-positive expression pattern appears to confer poorer outcome.
['Araki|Kyohei|K|', 'Miyata|Yasuyoshi|Y|', 'Nakamura|Yuichiro|Y|', 'Mukae|Yuta|Y|', 'Otsubo|Asato|A|', 'Yuno|Tsutomu|T|', 'Mitsunari|Kensuke|K|', 'Matsuo|Tomohiro|T|', 'Ohba|Kojiro|K|', 'Sakai|Hideki|H|']
D000368:Aged D000369:Aged, 80 and over D000971:Antineoplastic Combined Chemotherapy Protocols D003841:Deoxycytidine D019008:Drug Resistance, Neoplasm D005260:Female D006801:Humans D053208:Kaplan-Meier Estimate D008297:Male D008875:Middle Aged D017239:Paclitaxel D011379:Prognosis D011788:Quality of Life D019233:Retreatment D016896:Treatment Outcome D014571:Urologic Neoplasms
Gemcitabine paclitaxel urothelial cancer human antigen-R class III β-tubulin